Aptevo Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Aptevo Therapeutics de winst en omzet met respectievelijk 46% en 62.5% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 86.7% per jaar.

Belangrijke informatie

46.0%

Groei van de winst

86.7%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	62.5%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 May 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

DB:AP8 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	7	-24	N/A	N/A	2
12/31/2025	N/A	-28	N/A	N/A	2
12/31/2024	N/A	-28	N/A	N/A	2
3/31/2024	N/A	-27	-23	-23	N/A
12/31/2023	N/A	-19	-12	-12	N/A
9/30/2023	N/A	-18	-12	-12	N/A
6/30/2023	N/A	-19	-13	-13	N/A
3/31/2023	N/A	17	-11	-11	N/A
12/31/2022	3	7	-21	-21	N/A
9/30/2022	7	6	-19	-19	N/A
6/30/2022	10	6	-17	-17	N/A
3/31/2022	13	-30	-20	-19	N/A
12/31/2021	12	-29	-22	-22	N/A
9/30/2021	11	-30	-25	-24	N/A
6/30/2021	9	-30	-27	-26	N/A
3/31/2021	7	-29	-26	-26	N/A
12/31/2020	4	-31	-29	-29	N/A
9/30/2020	2	-33	-28	-28	N/A
6/30/2020	0	-37	-28	-28	N/A
3/31/2020	N/A	-41	-40	-40	N/A
12/31/2019	N/A	-43	-43	-42	N/A
9/30/2019	6	-48	-45	-45	N/A
6/30/2019	12	-49	-49	-48	N/A
3/31/2019	19	-52	-49	-48	N/A
12/31/2018	23	-54	-52	-51	N/A
9/30/2018	20	-49	-61	-60	N/A
6/30/2018	20	-34	-51	-50	N/A
3/31/2018	17	-35	-48	-47	N/A
12/31/2017	15	-33	N/A	-42	N/A
9/30/2017	15	-39	N/A	-33	N/A
6/30/2017	11	-115	N/A	-31	N/A
3/31/2017	4	-119	N/A	-35	N/A
12/31/2016	10	-120	N/A	-37	N/A
9/30/2016	15	-122	N/A	-38	N/A
6/30/2016	19	-61	N/A	-47	N/A
3/31/2016	30	-61	N/A	-47	N/A
12/31/2015	34	-59	N/A	-49	N/A
12/31/2014	46	-51	N/A	-47	N/A
12/31/2013	0	-53	N/A	-51	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat AP8 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat AP8 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat AP8 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat AP8 volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat AP8 volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van AP8 naar verwachting over 3 jaar hoog zal zijn

Aptevo Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Forecast to breakeven in 2022

Recent updates

Aptevo Therapeutics Expands on the Potential of Mipletamig

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial Initiated

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings released: EPS: US$1.38 (vs US$6.27 loss in FY 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$5.55 (vs US$1.78 loss in 2Q 2021)

Forecast to breakeven in 2022

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

First quarter 2022 earnings released: US$1.60 loss per share (vs US$1.74 loss in 1Q 2021)

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven